$6.97
-0.03 (-0.43%)
Open$7.02
Previous Close$7.00
Day High$7.09
Day Low$6.96
52W High$12.60
52W Low$4.85
Volume—
Avg Volume8.8K
Market Cap28.38M
P/E Ratio0.15
EPS$45.37
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+357.8% upside
Current
$6.97
$6.97
Target
$31.91
$31.91
$24.67
$31.91 avg
$44.05
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 6.49M | 18.13M | 5.44M |
| Net Income | 184.74M | 464.81M | -1,283,535 |
| Profit Margin | 2,848.6% | 2,706.2% | -23.6% |
| EBITDA | -52,092,843 | -138,351,134 | -2,024,078 |
| Free Cash Flow | — | — | -1,099,827 |
| Rev Growth | -64.2% | -64.2% | +18.0% |
| Debt/Equity | 0.08 | 0.08 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |